Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Bilenker Joshua H.
  2. Issuer Name and Ticker or Trading Symbol
Loxo Oncology, Inc. [LOXO]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President & CEO
(Last)
(First)
(Middle)
C/O LOXO ONCOLOGY, INC., 281 TRESSER BOULEVARD, 9TH FLOOR
3. Date of Earliest Transaction (Month/Day/Year)
04/24/2018
(Street)

STAMFORD, CT 06901
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 04/24/2018   M(1)   7,500 A $ 1.184 190,207 D  
Common Stock 04/24/2018   S(1)   1,717 (2) D $ 129.3516 (3) 188,490 D  
Common Stock 04/24/2018   S(1)   1,283 (2) D $ 130.6232 (4) 187,207 D  
Common Stock 04/24/2018   S(1)   1,500 (2) D $ 131.7567 (5) 185,707 D  
Common Stock 04/24/2018   S(1)   2,490 (2) D $ 132.5426 (6) 183,217 D  
Common Stock 04/24/2018   S(1)   510 (2) D $ 133.4851 (7) 182,707 D  
Common Stock 04/25/2018   M(1)   7,500 A $ 1.184 190,207 D  
Common Stock 04/25/2018   S(1)   800 (2) D $ 128.3045 (8) 189,407 D  
Common Stock 04/25/2018   S(1)   800 (2) D $ 129.4438 (9) 188,607 D  
Common Stock 04/25/2018   S(1)   2,400 (2) D $ 130.7121 (10) 186,207 D  
Common Stock 04/25/2018   S(1)   3,400 (2) D $ 131.8418 (11) 182,807 D  
Common Stock 04/25/2018   S(1)   100 D $ 132.53 182,707 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $ 1.184 04/24/2018   M(1)     7,500   (12) 11/14/2023 Common Stock 7,500 $ 0 37,190 D  
Employee Stock Option (right to buy) $ 1.184 04/25/2018   M(1)     7,500   (12) 11/14/2023 Common Stock 7,500 $ 0 29,690 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Bilenker Joshua H.
C/O LOXO ONCOLOGY, INC.
281 TRESSER BOULEVARD, 9TH FLOOR
STAMFORD, CT 06901
  X     President & CEO  

Signatures

 /s/ Jennifer Burstein, by power of attorney   04/26/2018
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
(2) Represents the aggregate of sales effected on the same day at different prices.
(3) Represents the weighted average sales price per share. The shares sold at prices ranging from $129.03 to $129.66 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
(4) Represents the weighted average sales price per share. The shares sold at prices ranging from $130.07 to $131.03 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
(5) Represents the weighted average sales price per share. The shares sold at prices ranging from $131.10 to $132.09 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
(6) Represents the weighted average sales price per share. The shares sold at prices ranging from $132.10 to $133.05 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
(7) Represents the weighted average sales price per share. The shares sold at prices ranging from $133.19 to $133.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
(8) Represents the weighted average sales price per share. The shares sold at prices ranging from $127.825 to $128.77 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
(9) Represents the weighted average sales price per share. The shares sold at prices ranging from $128.99 to $129.98 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
(10) Represents the weighted average sales price per share. The shares sold at prices ranging from $130.19 to $131.18 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
(11) Represents the weighted average sales price per share. The shares sold at prices ranging from $131.43 to $132.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
(12) The stock option is immediately exercisable in full, and vests as to 25% of the shares subject to the option on the one-year anniversary of the vesting commencement date, and thereafter as to 1/48th of the shares in equal monthly installments.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.